Reports of patients nonresponsive to antivirals used for the treatment of herpes simplex virus (HSV) infections are increasing (6, 14-16, 18, 25, 27) . In some of these clinically resistant cases, the virus has also been found to be resistant in cell culture assays to the drug used for treatment. For instance, two acyclovir (ACV)-resistant HSV mutants have been identified in immunodeficient children with ocular or skin herpes who had received multiple ACV treatments (7; C. D. Sibrack, L. T. Gutman, C. M. Wilfert, C. McLaren, and D. W. Barry, Pediatr. Res. 15:621) . In case of emergence during therapy or of recognition of drug-resistant viral strains of clinical significance, a potential approach, found to be most useful with bacterial infections (17) , is combination therapy. Therefore, we examined combinations of ACV and vidarabine (ara-A) or its 5'-monophosphate (ara-AMP) at various concentrations in cell culture and in mice, since these combinations are presently the ones most likely to be of broad clinical use.
Ara-A has several disadvantages when used at high dosage in humans (e.g., bone marrow suppression and renal and liver toxicity), and ACV can accumulate in patients with altered renal function when given intravenously (23, 24, 29) .
In addition, renal blockade or ACV crystallization has been reported to occur in the kidneys of dogs and humans receiving bolus systemic ACV (3, 20) . A combined modality may, therefore, reduce these host toxicities, since lower levels of each drug can be used.
(This work was presented in part at the 12th 500 SCHINAZI ET AL. sodium bicarbonate (24 mM) , and HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; 25 mM). The infected cells were incubated at 34°C for 3 to 4 days, until the cells could be easily shaken from the plastic surface of the culture bottles. The cells were collected by centrifugation, suspended in spent culture fluid (5 ml) , and sonicated three times for 1 min on ice. The disrupted cells were centrifuged (2,000 x g for 15 min at 4°C), the supernatant was diluted with an equal volume of sterile skim milk (as stabilizer), and portions were frozen at -70°C. YR assay. For the yield reduction (YR) assay, Vero cells were grown to near confluency (7 x 105 cells per well) in six-well plates (Costar, Cambridge, Mass.; 3.5-cm diameter) with medium supplemented with 10o inactivated NCS. The medium was removed, and virus (100 Il) was added to each well at an MOI of 1, unless otherwise stated. After 1 h of absorption at room temperature with intermittent rocking at 15-min intervals, the viral inoculum was removed by suction, and each well was washed twice with PBS. Freshly prepared solutions of test compounds, diluted to the desired concentrations in maintenance medium, were added in duplicate to the appropriate well (3 ml per well). In combination antiviral experiments, each compound was dissolved at appropriate concentrations and diluted with medium (2% NCS) to give the desired final concentrations. The infected cultures were then incubated at 37°C for 24 h in a 5% COz-95% air incubator (humdified), after which the plates were frozen at -70°C Uitil virus titrations were performed. Virus was released by freeze-thawing the medium-cell suspension twice. One part was transferred to tubes for storage at -70°C; the other part was diluted in absorption buffer, and the virus yield was assayed by plaquing on Vero cells in six-well plates. The number of PFU of virus in the drug-treated cultures relative to that found under drug-free conditions was determined. The problem of residual drug present in the virus dilutions was overcome by washing the cells in the plaque assay three times with PBS after virus absorption. In preliminary experiments, when virus was absorbed in the presence of high doses of ACV or ara-A (300 ,uM), this washing procedure resulted in a virus yield similar to that obtained in the absence of drug.
PR assay. For the plaque reduction (PR) assay, nearconfluent Vero cells in six-well plates were infected with virus (100 Jl) diluted in absorption buffer to give 100 to 200 plaques per well. The plates were incubated at room temperature for 1 h with intermittent rocking at 15-min intervals. The inoculum was removed by suction, and the cells were washed with PBS. The compounds at different concentrations (dissolved in maintenance medium containing 0.1% pooled human globulin [Cutter Biological, Berkeley, Calif.]) were then added in replicate. The plates were placed in a 5% COz-95% air incubator, and the plaques were allowed to develop for 48 h before fixation (10%6 buffered Formalin), staining (0.5% crystal violet in 20%o methanol in water), and enumeration with a dissecting stereomicroscop . The degree of inhibition was expressed as yield of control. (The use of agarose or carboxymethyl cellulose overlays resulted in the same yield as that obtained with human globulin).
Drugs. ACV was provided by G. Elion of Burroughs Wellcome Co. (Research Triangle Park, N.C.); ara-A was obtained from Sigma Chemical Co. (St. Louis, ANTIMICROB. AGENTS CHEMOTHER.
Mo.); ara-AMP was provided by M. L. Black of Wamer-Lambert Co. (Ann Arbor, Mich.). Drug solutions were prepared immediately before use in sterile PBS (pH 7.4) and filter sterilized (0.45-.Lm Millipore filter). It was necessary to warm the ara-A solution at 38°C to completely dissolve the drug. When this was not possible, as was the case in the animal studies, in which ara-A was used at concentrations greater than 0.5 mg/ml, the drug was micronized (<2-iLm diameter) and suspended in warm (38°C) sterile PBS.
isoation of resiant mutants. The ACV or ara-A mutants of HSV-1 strain F were selected in Vero cells by serially passaging the parent plaque-purified strain in the presence of ACV (5 ,uM) or ara-A (50 ,uM) at a low MOI (0.1). After three passages in the presence of either drug, the parent strain was found to have increased resistance. It was necessary to clone the viruses, as described by Field et al. (12) , to obtain the ara-A-resistant strains. Pools of cloned virus were prepared as described above. The virus titer was at least 108 PFU/ml. Titration of virues for drug scblit. The susceptibilities of the viruses to the drugs alone or in combination were determined by a PR assay. The susceptibilities of the mutants were compared to those of the parent strains, which had been simultaneously passaged at a low MOI the same number of times as the resistant mutants. The 50% effective dose was obtained from plots of log drug concentration (micromolar) versus percent reduction in plaque number. All values were the means of three determinations.
Drug toxicity assay In cells. Vero cells in medium (2.5 ml) supplemented with 10%0 NCS (growth medium) were added to eight 25-cm2 flasks (Falcon) at a concentration equivalent to 1/10 of cell confluency for each compound(s) tested (3 x 10' cells per flask). After incubation at 37°C in 5% CO2-95% air for 24 h, the test compound, dissolved in growth medium (2.5 ml), was added, and two flasks were harvested immediately by decanting the medium, washing once with PBS (5 ml), and then incubating at 37°C for 5 min with 3 ml of 0.125% trypsin-0.02% EDTA. The cells dislodged from the flask by the latter procedure were generally in clumps and were dispersed by repeated forceful pipetting of the suspension against the surface of the flask. To the well-dispersed cell suspension (1 ml), trypan blue solution (0.1 ml) was added, and the number of cells was counted with a hemacytometer. Each day for the next 3 days, two of the remaining flasks were harvested in the manner just described for determination of cell number. Infection of mice. Random-bred Swiss mice (female; 4 to 5 weeks old; 16 to 18 g) were obtained from Harlan-Sprague-Dawley Co. (Augusta, Me.). The animals were housed six to a cage and allowed to acclimatize to their new environment for 2 weeks. They were fed Rat Chow (Ralston Purina Co., St. Louis, Mo.), provided with tap water ad libitum, and kept on 12-h cycles of light and dark.
The mice were grouped so that the total weight of each group receiving a particular treatment was equal before an experiment (average weight of each mouse, 24 ± 1 g). Mice were anesthesized with Metofane (Pitman-Moore Co., Washington Crossing, N.J.) and inoculated (27-gauge needle) intracerebnlly with 0.05 ml of stock HSV diluted appropriately in sterile PBS (pH 7.4) (the virus was kept on ice during that proc-on November 28, 2019 by guest http://aac.asm.org/ Downloaded from COMBINATIONS OF ANTIVIRALS 501 ess). Inoculations were made into the right cerebral hemisphere with a microsyringe, and the virus titer was determined by a plaque assay in Vero cells immediately after infection of all the animals. Control animals were sham injected intracerebrally with PBS (0.05 ml). Mice that died within 24 h after injection were not included in our data (traumna).
Drug treatment. Mice were inoculated at noon (day 0) and treated with drug 5 h postinfection and twice daily thereafter at 9 a.m. and 5 p.m. Thus, there was a 16-h interval between the initial dose and the second dose. Drugs were injected in 0.5-mi doses intraperitoneally. In the combination regimens, drugs were administered in rapid sequence from separate syringes. Control animals were sham treated by intraperitoneal injection of PBS (0.5 ml) according to the drug dosage schedule described above. The fluctuation in weight of the animals during the 4 days of treatment was not sufficiently large to necessitate adjustment of the drug dose.
Mice that survived past day 21 were observed for another 2 months. Both treated and sham-treated animals were weighed daily for the first 4 days and every other day thereafter through day 21.
Drug toixdty In mice. The toxicity of the drugs alone and in combination for uninfected mice was determined following the same dosage schedule as that used in infected mice. Mice were weighed every other day.
Determination of virus in brains. The brains of dead mice were removed aseptically and frozen at -70°C in 2 ml of Hanks minimal essential medium containing 2% NCS, penicillin, and streptomycin. For titrations, the brains were thawed, finely minced, and homogenized. The suspension was frozen and thawed twice and centrifuged at 800 x g for 10 min at 4°C. The supernatant was tested in duplicate in Vero cells with 24-well plates (Costar) by plaque assay. Mice that survived for more than 3 months were sacrificed under anesthesia and evaluated for the presence or absence of virus in the brain by plaque assay. Statisfical analyses. Paired t tests were used for in vitro studies. The 50%0 lethal dose (LD50) was determined by the method of Reed and Muench (22 but less than the most effective agent alone, the reaction is subadditive; if YAB is greater than the most effective agent alone but less than the least effective agent, the reaction is termed interference; if YAB is greater than the least effective agent alone, the reaction is termed antagonism. The interaction that produces no inhibition greater than the most effective agent alone is called indifference.
RESULTS
Initially, a PR assay was used to determine the effect of ACV and ara-A alone or in combination. Numerous drug concentrations were tested (ACV, 0.05 to 5 ,uM; ara-A, 5 to 80 ,uM). Concentrations of drugs alone were selected from dose-response curves to produce 40 to 90% PR (yield of control = 0.6 and 0.1, respectively) with the F, G, and 333 strains of HSV. The results obtained with certain concentrations of drugs tested to exemplify some of the interactions observed, as well as the problems associated with this type of assay, are presented in Table  1 . Although the three HSV strains were found to be equally susceptible to ara-A, there were differences in their relative susceptibilities to ACV, the F strain (HSV-1) was the most susceptible, and the 333 strain (HSV-2) was the least susceptible. Combinations of all concentrations of the two drugs produced at least an additive effect, and at certain concentrations the effect was found to be synergistic.
Although the PR assay was useful for testing the various drugs alone and at low concentrations in combination, it could not be employed to examine the effect of combinations at high doses, since the resulting interaction reduced plaque numbers to close to, if not actually, zero. As exemplified in Table 1 , ACV (0.25 ,M) and ara-A (35 ,uM), when tested alone with the F strain, produced yields of control of 0.09 and 0.42, respectively. In combination, these agents produced an observed yield of control of less than 0.01 (i.e., less than two plaques). For an additive interaction, the calculated yield of control is 0.038 (i.e., seven plaques). Because of this problem, we explored the use of the YR assay for testing nontoxic high doses of drugs. Six-well plates proved particularly helpful for performing several YR experiments simultaneously, thus keeping the variables as constant as possible.
The results of the YR assay for ara-A and ACV alone are presented in Fig. 1 . Either drug alone decreased the yield of HSV-1 (strain F) to VOL. 22, 1982 on November 28, 2019 by guest http://aac.asm.org/ Downloaded from a greater extent than that of HSV-2 (strain G).
Since ACV was the more potent of the two drugs, the virus yields of control observed with combinations of the two drugs at various concentrations were compared with those obtained with ACV alone (Fig. 2 ). The addition of various concentrations of ACV to a fixed concentration of ara-A resulted in greater antiviral activity than either ACV or
n nni u ARA-A ara-A alone at an MOI of 1 (Fig. 2 and 3 ). The decrease in yield for either virus type was not significantly different from the calculated yield for an additive effect. Similar additive effects were noted when the concentration of ACV was fixed (0.5 ,uM) and ara-A (20 to 50 ,uM) was added, or when a lower MOI was used. ACV in combination with a fixed concentration of ara-AMP ( Fig. 2 and 3 ) or vice versa (data not shown) was found to produce an additive interaction with either the F or the G strain. Additive interactions were also obtained with combinations of ACV and ara-A (or ara-AMP) with clinical isolates of HSV, indicating that this effect is not limited to prototype strains.
To determine that the effects observed were not due to the toxicity of the drugs, the compounds alone or in combination were tested for any growth inhibition in Vero cells for 72 h ( Table 2 ). None of the combinations of ACV and ara-A (or ara-AMP) was noted to be more toxic to the cells than the agents alone, even with higher combined doses than those used in the experiments presented earlier. Ara-A at concentrations greater than 50 p.M was very toxic to rapidly dividing Vero cells. However, ACV at concentrations of 1 to 80 ,uM was not found to be toxic.
Mutants resistant to ACV (50% effective dose, >40 ,uM) were easily prepared when the F strain of HSV-1 was passaged twice in the presence of ACV (5 ,uM) . Ten plaques from the third passage in ACV were picked, and each plaque was tested for resistance to ACV. However, it was necessary to passage clones isolated from ara-Aresistant populations three times in the presence of ara-A (50 p.M) to obtain ala-A-resistant mutants (50% effective dose, >100 p.M). A total of five ara-A-resistant clones were prepared.
There was no cross-resistance between ACVresistant and ara-A-resistant mutants; the titer of the ACV-resistant viruses in the presence of ara-A and that of ara-A-resistant viruses in the presence of ACV were similar to that shown by the parent strain (data not shown). In addition, the ACVor ara-A-resistant mutants were as susceptible to the combination ACV/ara-A as the parent strain (range tested, 0.1/20 to 5/50 ,uM). Furthermore, mutants resistant to ACV, ara-A, or ACV/ara-A could not be obtained after passaging the parent strain three times in the presence of both ACV (5 to 10 ,uM) and ara-A (50 to 200 ,M) and then cloning the viruses.
Studies in mice. In view of the results obtained in cell culture, it was of interest to test combinations of the same drugs in mice inoculated with HSV. For this purpose, strain G (HSV-2) was chosen because, first, either ACV or ara-A in cell culture is generally more effective on HSV-1 than on HSV-2 strains (5, 8; Fig. 1) ; therefore, it would be expected that if a combination were effective in mice with HSV-2 strains it would also be effective with HSV-1 strains. Second, almost all the previous mouse studies with ACV have been done with HSV-1 strains (references given in reference 21); data obtained with HSV-2 are needed for comparison.
The LD50 for the G strain and two HSV-1 strains commonly used for mouse studies by other workers was determined for comparison in 6to 8-week-old mice. The G strain (LD5o/PFU = 4) was about 60-and 19,000-fold more virulent than the VR3 and F strains, respectively. A virus inoculum was selected which was sufficiently high to kill all animals in the untreated group within 4 days, since sharp endpoints for the virus control group were desirable to highlight differences from drug-treated animals.
By using a 4-day drug schedule, the response of infected mice with the equivalent of 560 LD50 (G strain) to treatment with ACV and ara-A (or ara-AMP) alone and in combination was ascertained (Table 3 ). Even though there was 100% Ara-AMP 50 23
ACV/ara-A 10/40 21 10/50 35 a The following compounds did not inhibit cell growth: ACV, 1 to 80 ,uM; ara-A or ara-AMP, 10 to 35 ,uM; ACV/ara-A or ara-AMP, 1/10, 1/20, 2.5/10, 2.5/20, 2.5/30, 10/10, and 10/20 ,uM. mortality with ACV (30 mg/kg per day) or ara-AMP (50 mg/kg per day), the mice died several days later than the untreated controls. The combination of these two compounds, at the same doses and schedule, significantly lowered mortality to 50%. To obtain the same final mortality with a single agent, doses of 40 and 80 mg of ACV or ara-AMP per kg per day, respectively, would be needed (Table 3) . When these two drugs were used in combination at the higher doses, mortality was significantly delayed (6.3 days for ACV alone versus 15 days for the combination), although the final mortality was not different (Tables 3 and 4 ). When ara-A was combined with ACV, the effect was at least as beneficial as that of ara-A alone; clearly, the dosages of ara-A in this experiment were too effective.
A second experiment, with dosages of individual drugs that allowed the virus to cause 75 to 90% mortality ( Table 3) , indicated that the combinations of ACV and ara-A or ara-AMP decreased mortality and significantly prolonged the life of infected animals, as compared with the drugs alone (Tables 3 and 4 ). The interaction of the combination of ACV and ara-A can be considered synergistic (better than additive), since the observed final mortality was 40% ( Ta-ble 3 ) and the expected value for an additive effect was 68% (90% x 75% x 100). This combination also appeared to be more effective than that of ACV and ara-AMP, since the final mortality in the ACV/ara-AMP group was not significantly different from that with either drug alone.
In the experiments described above, HSV was recovered from the brains of all virus-inoculated mice that died before day 9; the titers ranged from 4 x 102 to 8 x 105 PFU/g. The brains of most (>75%) of the infected animals that were treated with antivirals and died between days 9 and 21 were negative for HSV. Toxicity studies of ACV, ara-A, and ara-AMP alone and in combination at high and low drug dosages were determined in uninfected animals ( Table 5 ). At all the effective antiviral drug dosages for the combinations, no significant toxicity was noted except at ara-A dosages of greater than 200 mg/kg per day, when loss of weight occurred. At the higher dosages of ara-A in combination with ACV, the decrease in weight of the mice on day 7 appeared to be additive. DISCUSSION To be considered useful, antivirals in combination should have one or more of three advantages: at active drug concentrations, they must interact to produce at least an additive effect, i.e., no interference or antagonism should occur; they should produce no increased toxicity relative to the agents alone; and they should inhibit emergence of mutants resistant to either drug or their combinations.
None of the combinations of ACV and ara-A (or ara-AMP) studied in the YR assay in Vero cells resulted in interference or antagonism. Furthermore, all the concentrations of drug combinations determined by this assay with either HSV-1 or HSV-2 produced an additive interaction ( Fig. 2 and 3) . The degree of inhibition by the drug combinations was shown not to be the result of increased drug toxicity ( Table 2) .
In most cases, the drug combinations caused an additive effect when PR assays were used ( Table 1) . The occasional synergism observed was probably due to inherent problems with this type of assay. With some HSV strains, there is difficulty in counting plaque number because of the plaque size reduction induced by the antiviral drugs. As a result, the inhibitory effect of the drug can be overestimated, particularly at high concentrations, when few plaques are present. Unless proper precautions are taken, such as thorough cell washings, the YR assay can also result in an overestimation of the inhibitory effect, since residual drug could affect the virus titration (see Materials and Methods). An important advantage of the YR assay over the PR assay is the possibility of evaluating high concentrations of antivirals in combination. Furthermore, the YR assay appears to provide a more realistic model for what may occur clinically, in that certainly more than 102 infectious viruses (as commonly used in the PR assay) occur in infected sites. For these reasons, then, we elected to perform most of the combination studies with the YR assay.
The results obtained in cell culture were further substantiated in mice. Significant increases in survival time and reductions in mortality were noted when certain combinations of drugs were compared with the drugs used individually (Tables 3 and 4). The combination of ACV and ara-A was consistently more effective than that of ACV and ara-AMP at the doses tested. It is of interest that these combinations were effective at high intracerebral virus inocula (equivalent to 560 LD50). Moreover, no increase in mortality was noted with the dosages used for these combinations in uninfected animals. However, some adverse toxic effects (weight loss or failure to gain weight) were noted for certain combinations, particularly those with ara-A at dosages equal to or greater than 200 mg/kg per day (Table  5) . At high dosages, these combinations appeared to have additive toxicity.
It should be noted that the findings obtained in cell culture or mice do not preclude the possibility that arabinosyl hypoxanthine, produced from the deamination of ara-A or ara-AMP (19) , may be involved in the interaction with ACV. Champney and co-workers noted a synergistic effect between ara-A and arabinosyl hypoxanthine with HSV in cell culture (2) . It is unlikely, however, that interferon was involved in cell culture in our system, since Vero cells do not produce interferon when infected with viruses (9). Interaction of endogenous interferon with the antivirals used in the mouse studies, however, cannot be ruled out. Bryson and Kronenberg (1) have shown that interferon (HuIFN-P) and ara-A, ara-AMP, or arabinosyl hypoxanthine interact to produce additive effects in human fibroblast cells, and we have recently shown that interferon (HuIFN-,) and ACV in combination display an additive to synergistic effect in Vero cells, depending on the virus strain (26) . Nevertheless, it should be noted that the results of the drug combination studies were always compared with those obtained for the individual drugs alone. Therefore, it is likely that any effect due to other factors, such as arabinosyl hypoxanthine or interferon, noted with a combination would also occur with a single drug.
As antivirals become more widely used clinically for various forms of herpetic infection, the development or transmissibility of resistant mutants could increase over that uncovered so far (la, 7, 14, 16, 18; 27; Sibrack et al., Pediatr. Res. 15:621, 1981) . In cell culture, HSV mutants have been selected which are highly resistant to ACV. Since ACV resistance is conferred by the thymidine kinase or the DNA polymerase loci on the HSV genome and ara-A resistance is probably mediated by mutations in the DNA polymerase region (4) , cross-resistatice to ara-A can occur in thymidine kinase-positive ACV-resistant mutants (13) . However, the ACV-resistant mutants we have isolated so far in cell culture are thymidine kinase negative (data not shown) and are as susceptible to ara-A as the parent strain. We have also demonstrated the reverse, in that ara-A-resistant mutants are susceptible to ACV.
Several other ara-A-resistant viruses were also recently shown to be susceptible to low concen-trations of ACV (D. Coen, Sidney Farber Cancer Institute, Boston, Mass., personal communication). In addition, we have shown that ACVor ara-A-resistant HSV mutants are not likely to arise in the presence of the two drugs and that these resistant mutants are susceptible to the combination of ACV and ara-A. Experiments in mice are under way to determine whether ACVand ara-A-resistant strains are susceptible to various combinations of antivirals.
The results obtained so far with combination therapy in culture and in mice offer a different strategy for approaching the potential problem of HSV resistance in humans, particularly for life-threatening infections with these viruses. Furthermore, since lower dosages of drugs in combination can be used to achieve the same or greater effectiveness than either drug alone, the combined modality could be beneficial in treating immunosuppressed transplant patients or patients with impaired renal function, who cannot tolerate high dosages of the drugs.
